NBIX Stock Price Today (October 2026) — Neurocrine Biosciences, Inc. Analysis & Key Metrics 2026-10-20
Neurocrine Biosciences, Inc. (NBIX) is trading at $142.00, up 3.66% today (as of October 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $206.81 (45.6% upside).
- Volatility is low (24.87% annualized), implying relatively contained price movements for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (39.50% YoY) alongside competitive pressures in the Drug Manufacturers - Specialty & Generic space.
NBIX Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Neurocrine Biosciences, Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $14.51B
P/E Ratio
Forward P/E: 12.89
Revenue Growth
Year over Year
Analyst Target
+45.6% upside potential
Key Investor Questions About NBIX
What investors need to know before buying
Based on current market data, NBIX presents a neutral technical setup with looking solid fundamentals.
- Technicals say: Neutral (RSI 52.52)
- Fundamentals say: Looking solid (debt and growth supportive)
NBIX's growth trajectory depends on its ability to expand within the Drug Manufacturers - Specialty & Generic sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - Specialty & Generic operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for NBIX investors include debt exposure and competitive dynamics in the Drug Manufacturers - Specialty & Generic industry.
- $461.60M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - Specialty & Generic.
52-Week Trading Range
Over the past year, NBIX stock traded between $122.14 and $186.12 and currently trades in the middle of that range. Big swings are less likely unless a major catalyst emerges.
Volatility & Risk Profile
With 24.87% annualized volatility and β=0.67, the stock exhibits low sensitivity to market moves—making NBIX suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
Lower institutional support combined with high short selling points to negative sentiment.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines, coverage and TickZen analysis
Market news
Wedbush Cuts Price Target on Neurocrine Biosciences to $186 From $194, Keeps Outperform Rating
Neurocrine Biosciences (NBIX) Stock Trades Below Fair Value On Earnings
Axsome Therapeutics (AXSM) vs. Neurocrine Biosciences (NBIX): Is Faster Growth Worth Paying More For?
Latest TickZen Insights
All insights →No TickZen article on NBIX yet. Our newest analysis:
Explore More Analysis for NBIX
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 2, 2026 (after the close, usually)
Frequently Asked Questions
Common investor questions about Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. (NBIX) is currently trading at $142.00. The RSI (14-day) is at 52.5, indicating neutral territory. Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $206.81 implies 45.6% upside from current levels. Volatility is moderate at 24.9% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Neurocrine Biosciences, Inc. (NBIX): The trailing P/E ratio is 22.99, which is in line with broader market averages. The forward P/E is 12.89, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.46, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Book is 4.32. Price-to-Sales is 4.74. Valuation should be compared to Drug Manufacturers - Specialty & Generic industry peers for context, as different sectors trade at different multiples.
Based on 29 analysts covering NBIX, the consensus price target is $206.81. This represents a 45.6% upside from the current price of $142.00. The range spans from a low target of $150.00 to a high target of $253.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Neurocrine Biosciences, Inc. (NBIX) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Neurocrine Biosciences, Inc. (NBIX) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Drug Manufacturers - Specialty & Generic sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Neurocrine Biosciences, Inc.'s (NBIX) current debt and financial health profile: Total debt stands at $461.60M. The debt-to-equity ratio is 0.12x, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 1.87, indicating strong short-term liquidity. The quick ratio is 1.46. The company holds $389.80M in cash and equivalents. Free cash flow is positive at $638.24M, providing a cushion for debt servicing and shareholder returns.